Neumora Therapeutics, Inc. Common Stock
- NMRA
- NASDAQ
- Biotechnology
- Neurology/Psychiatry Biotech
- Clinical-Stage Therapeutics
$0.47
Today +10.96%Quote Oct 16, 2026, 08:00 PM UTC
−36.83%over the last month
Max drawdown −54.5%From 1-month high −39.1%3 months −70.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$89.0M
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$4.50
+849.8% from here
Floor
$0.44
7.6% below price
Where the price sits
9 analysts
Analyst range, low to high
$4.00$5.00
- Price $0.47
- Resistance $0.49
- Consensus $4.50
Analysts' average target sits about 850% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NMRAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
63